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Pain can be classified broadly 
into two categories, nociceptive and 
neuropathic, characterised by different 
clinical presentations and underlying 
pathophysiological mechanisms. (Table 1)
The WHO analgesic “ladder”
The WHO guidelines were first published 
in 1986  and are considered to be  the gold 
standard for managing pain in advanced 
cancer.3 Figure 1 gives a schematic diagram 
of the recommended “analgesic ladder” 
Non-opioids include non-steriodal 
anti-inflammatory drugs (NSAIDs), 
paracetamol and adjuvant analgesia. 
Adjuvant drugs include antidepressants, 
anticonvulsants, antispasmodics, steroids 
and bisphosphonates. 
Choice of analgesia
Non-opioid
•	 Paracetamol
 Despite being a widely used drug and 
available for a very long time, the 
mechanism of action for paracetamol still 
remains unclear. The standard explanation 
is that it acts as a cyclo-oxygenase 
inhibitor in the brain, explaining both its 
analgesic and its antipyretic properties.4  
It is also thought to be involved 
with serotonin modulation pathways.  
Ultimately paracematol remains a 
safe, well tolerated and effective 
drug especially in the management of 
mild to moderate pain. It can also be 
administered with other analgesia to 
achieve an additive effect. The main 
problem is hepatotoxicity especially in 
overdose. 
•	 Non-steroidal	anti-inflammatory	drugs	
(NSAIDs)
 NSAIDs are useful in treating mild 
to moderate pain mediated by 
prostaglandins, which serve to sensitise 
nociceptors.5  They are of particular 
benefit for pains associated with 
inflammation. In spite of insufficient 
evidence,  NSAIDs have traditionally been 
used in the palliation of metastatic bone 
pain although radiotherapy remains the 
treatment of choice.6 
 NSAIDs inhibit cyclo-oxygenase (COX), an 
important enzyme in the arachidonic acid 
cascade which results in the production of 
tissue and inflammatory prostaglandins. 
 COX exists in two forms. COX-1 is 
“constitutive” i.e is part of the body’s 
normal physiological constitution with 
near constant levels and activity in 
most tissues, including the central 
nervous system (CNS). COX-2 expression 
is generally low or non-existent but is 
“inducible” i.e. is massively produced 
within a few hours by inflammation.7 The 
main exceptions to this are parts of the 
central nervous system (CNS), kidneys 
and seminal vesicles which contain high 
levels of COX-2 (Figure 2). 
 Non-specific COX inhibitors, such as 
aspirin, ibuprofen, diclofenac and 
naproxen inhibit both isoenzymes 
to produce analgesia.  However this 
also leads to adverse effects typically 
observed as gastrointestinal and renal 
toxicity.
Opioids
Opioids include all drugs that act at 
opioids receptors, (mu, kappa, delta and 
ORL-1), distributed in varying densities 
throughout the body, particularly in the 
nervous system. Agonism at these receptors 
produces analgesic effects observed with 
opiates. 
Codeine is usually the drug of choice 
for mild to moderate pain (step 2, WHO 
analgesic ladder). Its analgesic effect is 
largely due to its metabolism to morphine by 
cytochrome CYP2D6.  Codeine is considered 
one tenth as potent as morphine. As a 
general rule, products containing less than 
30mg of codeine per dose are not suitable 
step 2 analgesia. Although classified as a 
weak opioid, patients taking codeine still 
present with typical opioid adverse effects 
including nausea, vomiting, sedation and 
constipation. However, unlike morphine 
weak opioids have a “ceiling dose”, 
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Pain occurs in 40 to 80% of patients with advanced progressive 
disease.1  Despite the publications of various guidelines and research 
in this area together with an extensive choice of analgesia, pain 
management still presents a challenge in everyday practice.  Pain is 
defined as an unpleasant sensory and emotional experience associated 
with actual or potential tissue damage2 or in simpler terms “pain is 
what the patient says hurts.”
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Table 1. Mechanism of pain and implications for treatment
Type of pain Mechanism Examples  Typical treatment
Nociceptive
Muscle spasm Stimulation of  Cramp  Muscle relaxants
Somatic nerve endings Soft tissue, bone pain NSAIDs ± opioid
Visceral  Liver capsule pain 
     
Neuropathic
Nerve compression Pain transmitted  Neuroma or nerve   Opioid +   
Nerve injury from damaged infiltration eg   corticosteroid
De-afferentation pain neural tissue in brachial or     
Central pain either the lumbosacral plexus  Opioid, NSAID,  
 peripheral Spinal cord  tricyclic   
 or central compression  antidepressant,  
 nervous system   anti-epileptic,  
    NMDA-receptor- 
    channel blocker,  
    spinal analgesia
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Step 1
Step 2
Step 3
Non-opioid ± adjuvants
Weak opioid + non-opioid ± adjuvants
Strong opioid + non-opioid  ± adjuvants
Figure 1. WHO 3-step Analgesis ladder
Table 2. Commonly prescribed adjuvant analgesia in the management of caner pain.
Indication Drugs
Neuropathic pain Amitriptyline, gabapentin, 
 clonazepam, dexamethasone
Neuropathic pain (unresponsive to the above) Ketamine
Bowel obstruction Hyoscine butylbromide, octreotide
Metastatic bone pain Pamidronate, zolendronate, dexamethasone
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PGH2
Membrane phospholipids
Arachidonic acid
5-LOX COX1 or COX2
5-HPETE PGG2
Leucotriene A4 
Leucotriene B4  Cysteinyl leucotrienes
Prostacyclines
Prostaglandins
Thromboxanes
Allergy, inflammation, gastric damage
Inflammation, pain, gastroprotective PG
Figure 2. Products of arachidonic acid metabolism involved in inflammation
Key: COX – cyclo-oxygenase, 5-HPETE – hydroperoxyeicosatetraenoic acid, LOX – lipoxygenase, PG- prostaglandin
Non-specific COX inhibitors, such as aspirin, ibuprofen, diclofenac and naproxen inhibit both isoenzymes to produce 
analgesia.  However this also leads to adverse effects typically observed as gastrointestinal and renal toxicity.
above which any increase in analgesia is 
outweighed by progressively more adverse 
effects. For codeine, this is typically 240mg 
over 24 hours. When the ceiling dose has 
been reached, step 3 treatment should be 
introduced.8    
Morphine remains the drug of choice 
for moderate to severe pain (step 3, WHO 
analgesic ladder).  It is a potent mu receptor 
agonist. The liver is the predominant site 
of metabolism where it is converted to two 
main forms: morphine-3-glucuronide (M3G) 
and morphine-6-glucuronide (M6G). M6G 
produces potent opioid effects whereas the 
pharmacology of M3G remains unclear. Both 
metabolites are renally excreted so patients 
with renal failure are at a greater risk of 
opioid toxicity.  
The starting dose of morphine depends 
on whether or not the patient has been 
previously exposed to opioids and at 
which dose. For opioid-naïve patients, an 
immediate release formulation should be 
prescribed and the dose of morphine titrated 
according to response. Typically, 5 to 10mg 
every four hours is used with the option for 
further doses if the pain is not controlled 
with four hourly dosing. Once the morphine 
requirement over 24 hours is established, 
slow release preparation may be prescribed.  
The patient should be advised to expect 
sedation, nausea and vomiting during the 
titration period although tolerance develops 
with these adverse effects. However, 
tolerance does not develop to constipation 
and regular laxatives should be prescribed. 
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It has long been observed anecdotally 
that patients who develop intolerable 
adverse effects to morphine while achieving 
inadequate analgesia may sometimes 
benefit from switching to an alternative 
opioid.9  The initial dose of the second 
opioid depends on the relative potency of 
the two drugs. This again is a huge area of 
controversy and any equianalgesic tables 
should be considered with caution as there 
is lack of comprehensive data and inter-
patient variation. Special caution should be 
exercised when converting a patient from 
high dose morphine to another opioid as 
the recommended equivalent doses become 
progressively less accurate as the dose 
increases. Therefore, when converting at 
high dose, it is best to give lower than the 
calculated equivalent doses and rely on “as 
required” doses to make up any deficit while 
re-titrating to a satisfactory dose of the new 
opioid. Some examples of alternative opioids 
are discussed below.
Oxycodone is a stronger opioid than 
morphine. Oxycodone is one and a half 
to two times more potent than morphine. 
Its opioid receptor site affinities remain 
controversial but apart from µ receptor 
activity it is thought to have agonist effects 
on receptors as well.10  It is better tolerated 
than morphine especially in patients 
experiencing hallucinations. 
Similarly fentanyl is a stronger opioid 
than morphine. It has a low molecular 
weight and is lipophilic making it suitable 
for transdermal and oral transmucosal 
administration. Fentanyl patches are applied 
to the skin for 72 hours and a reservoir of 
fentanyl is formed in the fatty tissue under 
the skin. Analgesia is not achieved for at 
least 12 hours after the first patch is applied 
and steady state may not be achieved for 
up to 48 hours so analgesic benefit should 
not be assessed until three days after the 
first patch is applied. Once steady state 
is attained, the plasma half life can be up 
to 25 hours. Transdermal fentanyl can be 
considered an option for patients with renal 
impairment, severe constipation, dysphagia 
or bowel obstruction. 
Methadone is reserved for patients with 
pain refractory to conventional treatment 
due to its complicated pharmacokinetics 
which can lead to accumulation. There is a 
lack of potency ratio between methadone 
and morphine and it should only be initiated 
by specialists in pain management. One 
major advantage is that methadone is also 
an N-methyl-D-aspartate (NMDA)-receptor 
channel blocker in addition to opioid 
agonism and has benefits in managing 
neuropathic pain. 
Adjuvant analgesia
Adjuvant analgesia tend to be drugs that 
are licensed for indications other than pain. 
Hence they are not primarily classified as 
analgesia even though they may relieve pain 
that is usually not responsive to standard 
analgesia. These include steroids, anti-
depressants, anti-epileptics, bisphosphonates 
and antispasmodics. Commonly prescribed 
adjuvant analgesia are listed in Table 2.
The choice of drugs depends on type 
of pain (nociceptive or neuropathic), co-
existing morbidity and current medication. 
Adjuvants can also have opioid sparing 
effects and the opioid dose should be 
reviewed when initiating adjuvant analgesia. 
There is a risk of additive toxicity from 
polypharmacy, as adjuvant analgesia are 
typically administered to patients who are 
receiving several other drugs. The potential 
for additive side-effects must be considered 
prior to prescribing. The decision to add or 
continue a treatment must be based on a 
careful assessment of outcomes and a clear 
understanding of the goals of care. 
Conclusion
Pain is one of the commonest symptoms 
of advanced cancer and probably the 
most dreaded by patients. However, the 
majority of patients with cancer pain can 
be well managed as long as analgesia is 
used appropriately and assessed regularly. 
Many patients are frightened of opioids, 
particularly morphine due to its possible 
connotations with death. It is vital to 
explore their fears before starting the 
drug and ensure that support is provided. 
Strategies should be in place to manage side 
effects as most can be easily managed but 
can have devastating effects if ignored or 
not addressed appropriately. 
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Practice points
•	 Pain	is	still	one	of	the	commonest	symptom	experienced	by	cancer	patients,	however	
it can be managed well in the majority of patients if the correct analgesia and 
appropriate dose escalations are used.
•	 The	WHO	analgesic	ladder	remains	the	gold	standard	for	managing	pain.
•	 NSAIDs	have	traditionally	been	used	in	metastatic	bone	pain,	although	evidence	
in this setting is limited. Radiotherapy remains the treatment of choice and 
these patients should be referred to oncology/palliative services to ensure best 
management.
•	 Patients	should	be	counselled	on	adverse	effects	of	opioids	and	appropriate	
medication prescribed to avoid preventable adverse effects.
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